Partnering: VasoDynamics Signs a Long-term Partnership Agreement with Cambrex for the Supply of Active Pharmaceutical Ingredients

2nd -December- 2025

VasoDynamics Ltd, the pharmaceutical company developing patient-friendly cost-effective therapies for the prevention/reduction of debilitating side-effects induced by anti-cancer treatments, is pleased to announce the signing of a long-term partnership with Cambrex Profarmaco Milano S.r.l. for the supply of active pharmaceutical ingredients (API) for VasoDynamics’ late-clinical stage pharmaceutical products, in preparation for global registration trials and future global commercialisation.

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are delighted to partner with Cambrex for its large-scale supply capacity and long-standing record of producing high-quality API as well as providing the associated technical and regulatory support for our three topical vasoconstriction products, ahead of global registration trials and commercialisation in the near future.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO fiona.li@vasodynamics.co.uk